China Investors Rush to Exit After Crackdown on Illicit Overseas Stock Trading TechnologyDriven Healthcare Transformation Ushering a New Era of Medicine China Signals Openness to Deal Preserving TikToks US Operations Following ByteDance FounderMusk Meeting US Consumer Prices Accelerate 38 in April Marking Highest Annual Gain Since May 2023 Meta Broadcom and Industry Leaders Launch 125 Million Semiconductor Research Hub at UCLA Russian Oil Arrivals in Singapore Increase Amid Legal Trade Framework InMed Pharmaceuticals Q3 2025 Earnings Continued Losses as Stock Declines CTGO Q1 2026 Earnings Significant EPS Miss Raises Concerns FLNA Q3 2025 Earnings NarrowerThanExpected Loss Drives Stock Rally TOMI Environmental Solutions Q1 2026 Earnings NarrowerThanExpected Loss Ignites Stock Rally Talen Energy TLN Q1 2026 Earnings EPS Misses Wall Street Estimates by 72 Stock Edges Higher Atossa Therapeutics Q1 2026 Earnings Narrowed Loss Beats Estimates as Clinical Pipeline Advances GSI Technology GSIT Declines 2 as Shares Approach Critical Support Level Plug Power PLUG Rises 217 as Green Hydrogen Sector Finds Its Footing Solid Power Warrants Surge 1765 Momentum Builds After Key Support Test Cohen Steers ClosedEnd Opportunity Fund FOF Edges Higher Key Levels in Focus Delixy Holdings DLXY Edges Higher as Stock Tests Key Resistance Healthcare and Tech Lead SP 500 to Modest Gains Communication Services Lags WEYS Q1 2026 Earnings Solid EPS Performance Amid Limited Disclosure Devon Energy Holds Steady Near 44 as Traders Eye Key Levels DVN Infrastructure Control Emerges as Potential Financial Advantage in Modern Markets SK Hynix Posts Record Profit on AIDriven Chip Demand Analyst Report Highlights Viatris Incs Strategic Positioning Amid Generic Drug Competition Adani Power Surpasses Infosys in Market Cap Amid 66 YTD Rally Micron and SK Hynix Join 1 Trillion Club Samsung Defuses Strike Threat Amid Tech Stock Dip RBI Resists Rate Hikes for Rupee Defense Prioritizes Inflation Control Sources Viatris Inc Analysts Weigh PostMerger Strategy and Generic Drug Portfolio Outlook